Drug-Releasing Coating With Ionic Additives for Tissue Retention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing drug-releasing coatings for treating strictures and stenoses are limited by inefficiencies in drug transfer, tissue retention, and recurrence of strictures, requiring repeated interventions.

Innovation Solution

A drug-releasing coating comprising polymer-encapsulated drug particles with ionic or zwitterionic additives, a release matrix, and a topcoat layer, applied to balloon catheters for targeted delivery to treat strictures and stenoses, enhancing drug transfer and retention.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional drug-releasing coatings are used, then the treatment can be applied to strictures and stenoses, but the drug transfer efficiency is low and tissue retention is poor

Engineering Contradiction:

Improvedrug transfer efficiencyVSAvoiddrug retention in tissue

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent employs a composite coating formulation consisting of multiple polymers (e.g., polyethylene glycol, polyvinyl alcohol, gelatin) combined with specific drug molecules (e.g., sirolimus, paclitaxel). This composite approach creates a synergistic effect where the polymer matrix enhances drug stability and controlled release while the drug provides therapeutic action, thereby improving both drug transfer efficiency and tissue retention compared to conventional single-component coatings

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The patent optimizes physical and chemical parameters of the coating including drug-to-polymer ratios, molecular weights of polymers, coating thickness, and crosslinking density. By systematically adjusting these parameters, the formulation achieves enhanced drug transfer efficiency through improved solubility and diffusion characteristics while simultaneously increasing tissue retention through optimized adhesion properties

Inventive Principle:

Principle #35Parameter changes

2Reliability

If conventional drug-releasing coatings are used, then the procedure can be performed, but recurrence of strictures occurs frequently

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtime until stricture recurrence

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

The patent applies drug-containing coating to the balloon catheter surface before the dilation procedure. The pre-applied coating ensures that therapeutic agents are delivered directly to the stricture site during the procedure, preventing recurrence before it can occur. This preliminary drug delivery approach is more effective than post-procedure treatments by addressing the underlying pathology at the time of intervention

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent utilizes controlled-release polymer matrices that maintain continuous drug delivery to the treated tissue over an extended period. The polymer degradation and drug diffusion are engineered to provide sustained therapeutic concentrations, ensuring continuous anti-proliferative or anti-inflammatory action that prevents stricture recurrence throughout the healing process and beyond

Inventive Principle:

Principle #20Continuity of useful action

3Reliability

If higher doses of therapeutic agents are used to improve treatment outcomes, then clinical efficacy increases, but systemic exposure and side effects increase

Engineering Contradiction:

Improveclinical efficacyVSAvoidsystemic exposure to drug

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent delivers therapeutic agents locally to the stricture or stenosis site through the balloon catheter coating, concentrating the drug effect precisely where needed. This localized delivery achieves high clinical efficacy at the treatment site while minimizing systemic circulation of the drug, thereby reducing systemic side effects and exposure compared to systemic administration routes

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The coating achieves higher drug transfer efficiency, improved tissue adhesion, and reduced recurrence of strictures, with enhanced clinical outcomes and lower systemic exposure to therapeutic agents.

Implementation Method 1

The polymer-encapsulated drug particles can include a first ionic or zwitterionic additive. The first ionic or zwitterionic additive can be in the polymer-encapsulated drug particles, coated on a surface of the polymer-encapsulated drug particles

Methodology Applied

Scientific EffectIonic or zwitterionic interaction: Ion Repulsion/Attraction

Implementation Method 2

The polymer-encapsulated drug particles can include a therapeutic agent, one or more polymers that encapsulate the therapeutic agent

Methodology Applied

Scientific EffectPhysical containment: Physical Containment

Data Source

PatentUS20260041821A1Drug-releasing coating

Publication Date: 2026.02.12 TONIC MEDICAL INC

AI summary

A drug-releasing coating includes polymer-encapsulated drug particles including a therapeutic agent, one or more polymers that encapsulate the therapeutic agent, and a first ionic or zwitterionic additive. The first ionic or zwitterionic additive is in the polymer-encapsulated drug particles, coated on a surface of the polymer-encapsulated drug particles, or a combination thereof. The drug-releasing coating also includes a release matrix including a second ionic or zwitterionic additive.